Cardiovascular Diabetology · 2021 · 143 citations · 26 references
MedicineCardiologyInternal MedicineClinical CardiologyClinical EpidemiologyEpidemiologic MethodsCardiac Risk AssessmentCardiovascular DiseaseCardiovascular RiskDiabetes MellitusInsulin ResistanceMyocardial Infarction ComplicationsCerebral ComplicationsDiabetes-associated Cardiac RiskDiabetes-related ComplicationsInsulin Resistance AssessmentPost-myocardial Infarction Complications
Abstract Background Triglyceride glucose (TyG) index is considered a reliable alternative marker of insulin resistance and an independent predictor of cardiovascular (CV) outcomes. However, the prognostic value of TyG index in patients with type 2 diabetes mellitus (T 2 DM) and acute myocardial infarction (AMI) remains unclear. Methods A total of 1932 consecutive patients with T 2 DM and AMI were enrolled in this study. Patients were divided into tertiles according to their TyG index levels. The incidence of major adverse cardiac and cerebral events (MACCEs) was recorded. The TyG index was calculated as the ln [fasting triglycerides (mg/dL) × fasting plasma glucose (mg/dL)/2]. Results Competing risk regression revealed that the TyG index was positively associated with CV death [2.71(1.92 to 3.83), p < 0.001], non-fatal MI [2.02(1.32 to 3.11), p = 0.001], cardiac rehospitalization [2.42(1.81 to 3.24), p < 0.001], revascularization [2.41(1.63 to 3.55), p < 0.001] and composite MACCEs [2.32(1.92 to 2.80), p < 0.001]. The area under ROC curve of the TyG index for predicting the occurrence of MACCEs was 0.604 [(0.578 to 0.630), p < 0.001], with the cut-off value of 9.30. The addition of TyG index to a baseline risk model had an incremental effect on the predictive value for MACCEs [net reclassification improvement (NRI): 0.190 (0.094 to 0.337); integrated discrimination improvement (IDI): 0.027 (0.013 to 0.041); C-index: 0.685 (0.663 to 0.707), all p < 0.001]. Conclusions The TyG index was significantly associated with MACCEs, suggesting that the TyG index may be a valid marker for risk stratification and prognosis in patients with T 2 DM and AMI. Trial registration Retrospectively registered.
26
K. G. M. M. Alberti, Paul Zimmet · Diabetic Medicine · 1998 · 15.3K citations
Fernando Guerrero‐Romero, Luis E. Simental‐Mendía, Manuel González-Ortı́z et al. · The Journal of Clinical Endocrinology & Metabolism · 2010 · 2.3K citations · Full text
Medicine, Endocrinology, Diabetology +15